Description: Bead lysis kits for the homogenization of small, soft or medium-tough samples. Pack of 250, 1.5mL RINO screw-cap tubes prefilled with stabilized ceramic beads. RNase free.

Description: Bead lysis kits for the homogenization of large, soft or medium-tough samples. Pack of 100, 5mL Eppendorf Safe-Lock tubes prefilled with stabilized ceramic beads. RNase free.

Description: Bead lysis kits for the homogenization of large, soft or medium-tough samples. Pack of 20, 5mL Eppendorf Safe-Lock tubes prefilled with stabilized ceramic beads. RNase free.

Description: Bead lysis kits for the homogenization of large, soft or medium-tough samples. Pack of 50, 1.5mL RINO screw-cap tubes prefilled with stabilized ceramic beads. RNase free.

Description: Bead lysis kits for the homogenization of large, soft or medium-tough samples. Pack of 250, 1.5mL RINO screw-cap tubes prefilled with stabilized ceramic beads. RNase free.

Description: Bead lysis kits for the homogenization of small cell suspensions (ex - E. coli). Pack of 50, 1.5mL RINO screw-cap tubes prefilled with stabilized ceramic beads. RNase free.

Description: Bead lysis kits for the homogenization of small cell suspensions (ex - E. coli). Pack of 250, 1.5mL RINO screw-cap tubes prefilled with stabilized ceramic beads. RNase free.

Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again.

Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.

Description: Antibody raised against SARS

Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies.

Description: Severe acute respiratory Coronavirus 2 RNA dependent RNA polymerase, GenBank Accession No. YP_00972530, a.a. 1-932(full length), with an N-terminal FLAG-tag expressed in a HEK293 expression system. MW=108 kDa.

Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications.

Description: Antibody raised against Pan-PAX